Jefferies downgrades Genmab recommendation due to lack of short-term catalysts

A lack of short-term catalysts is one of the reasons that investment bank Jefferies has changed its recommendation for Genmab stock. The biotech company's share price increase since the start of the year is another reason, as S&P's biotech index has fallen during the same period.

Photo: Tuala Hjarnø / Genmab / PR

US-based investment bank Jefferies has downgraded its recommendation for Genmab from "buy" to "hold," as the share price has risen by around 10 percent since the start of the year and 40 percent since March, while S&P's index has fallen 9 percent since the New Year.

The brand new analysis from the bank states that a lack of short-term catalysts is another reason that it has changed its recommendation. The next big news expected from the company is the results of the extended study of Epcoritamab (CD3xCD20) for the treatment of Leukemia, which Jefferies expects to be publicized in summer 2022.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs